References in periodicals archive ?
Objective: Bone marrow (bm) fibrosis is the continuous replacement of blood forming cells in the bone marrow by scar tissue, Ultimately leading to failure of the body to produce blood cells.
Clinical manifestations like ascites or splenomegaly help point to the diagnosis of cirrhosis but the early detection of fibrosis is not possible by simple grey scale ultrasound as these features generally emerge late.
Predetermined cutoffs of biomarkers of fibrosis and activity are used to rank the severity of liver disease from low-risk status to cirrhosis (F4.
20 November 2015 - US-based non-profit The Pulmonary Fibrosis Foundation has acquired all rights to the Daughters of Pulmonary Fibrosis programme from the Coalition for Pulmonary Fibrosis, a California-based 501c3 nonprofit public benefit organisation serving the pulmonary fibrosis community, The PFF said.
M2 EQUITYBITES-November 20, 2015-Pulmonary Fibrosis Foundation Acquires Daughters of Pulmonary Fibrosis Programme
AbstractWith increasing innovations aimed at the treatment of chronic liver disease (CLD) the precise staging of liver fibrosis is important to help establish efficacious management of disease activity in each patient.
The company will use the funds for the development of new therapy for lung fibrosis.
According to the study published online in Hepatology, a journal of the American Association for the Study of Liver Diseases, men are at higher risk of more severe fibrosis compared to women prior to menopause, but liver fibrosis severity is similar in men and post-menopausal women.
11 ( ANI ): Scientists have found a new way to intervene in the molecular and cellular cascade that causes fibrosis - a condition where the body's natural process of forming scars for wound healing goes into overdrive and causes diseases.
Last summer, for instance, Walgreens teamed up with the Cystic Fibrosis Foundation to open a specialty pharmacy unit aimed at patients suffering from the genetic disease.
MANY people with Cystic Fibrosis are living longer than ever before thanks to advances in treatment and access to clinical expertise.
Among their topics are screening newborns for cystic fibrosis, cystic fibrosis and respiratory viral infections, neutrophil elastase-mediated modulation of pathophysiology in cystic fibrosis lung disease, genotype heterogeneity of the molecular basis of cystic fibrosis as the paradigm of Lithuanian population genetic testing, serum transferrin microheterogeneity in cystic fibrosis, recommendation for good practice and analytical criteria of the methods used in the sweat test, ocular surface changes in patients with cystic fibrosis, and managing arthritis related to cystic fibrosis.